Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?

Table 4 Early evaluation of tumor response to sunitinib by RECIST 1.1 and Choi criteria

No. of patient	Change in tumor size (%)	Change in tumor density (%)	RECIST 1.1 response	Choi response	TTP (m)
1	−34	−15	PR	PR	16.6
2	−42	−21	PR	PR	6.4
3	−45	11	PR	PR	18.5
4	−50	−54	PR	PR	13.0
5	−15	3	SD	PR	7.4
6	5	−15	SD	PR	22.8
7	−6	−18	SD	PR	20.5
8	−9	−34	SD	PR	2.4
9	−3	−8	SD	SD	10.8
10	5	−5	SD	SD	15.1
11	4	−3	SD	SD	5.9
12	3	−5	SD	SD	12.6
13	11	5	SD	PD	5.7
14	11	−1	PD^a	PD	1.4
15	27	9	PD	PD	3.1
16	15	−4	PD^a	PD	2.3
17	24	1	PD	PD	2.1
18	21	8	PD	PD	2.5

^aThe Progressive Disease of RECIST version 1.1 was the result of new lesions at the first follow up by CT scan, rather than the increase of tumor size

ISSN: 1471-2407